Approvals
Decisions by the FDA and other regulators on new drugs, biologics and devices.
Stories
-
FDA approves Voceryq for adults with recurrent respiratory papillomatosis
Seven of 26 adults with at least three baseline surgeries (27%) needed no surgery in the first year after Voceryq, the FDA said in granting accelerated approval. Adults with recurrent respiratory papillomatosis now have a plasmid DNA-based immunotherapy approved in the U.S.
-
FDA approves first plasmid DNA-based immunotherapy for adults with RRP
The FDA granted accelerated approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for adults with recurrent respiratory papillomatosis, a rare disease caused by HPV. In an open-label multicenter trial of 32 adults, 27% of patients who had at least three baseline surgeries did not require any surgery during the first year after treatment.
-
FDA approves talazoparib with enzalutamide for HRR gene-mutated prostate cancer
The FDA approved talazoparib with enzalutamide for metastatic prostate cancer with HRR gene mutations after TALAPRO-3 showed a hazard ratio of 0.48 for radiographic progression-free survival. It adds an approved use for androgen pathway modulation-naïve or -sensitive disease.
-
FDA approves once-weekly Awiqli for children 10 and older with type 2 diabetes
The FDA approved Awiqli, a once-weekly insulin, for pediatric patients aged 10 years and older with type 2 diabetes mellitus, based on a single-dose study in 18 pediatric patients. Pediatric patients now have an approved once-weekly insulin, the FDA said.
-
FDA approves talazoparib with enzalutamide for metastatic prostate cancer
On October 26, 2026, the FDA approved talazoparib (Talzenna, Pfizer Inc.) in combination with enzalutamide for adults with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with homologous recombination repair gene mutations, as detected by an FDA-authorized test. The TALAPRO-3 trial showed median radiographic progression-free survival not reached (95% CI: NR, NR) versus 45.8 months (95% CI: 37.7, NR) with a hazard ratio of 0.48 [95% CI: 0.36, 0.65]; p<0.0001.
-
FDA approves first once-weekly insulin for type 2 diabetes in pediatric patients
Awiqli (insulin icodec-abae) is approved for children aged 10 years and older with type 2 diabetes mellitus. The drug is administered by subcutaneous injection once weekly and was approved after a priority review.
-
FDA grants traditional approval for pembrolizumab in TMB-H tumors; 36% had an objective response
The FDA granted traditional approval to pembrolizumab for TMB-H solid tumors; the objective response rate was 36% (95% CI: 30, 43) in 220 patients in KEYNOTE-158. The approval defines TMB-H as 13 or more mut/Mb, up from the 10 mut/Mb used in the accelerated approval.
-
FDA approves first generic of Climara Pro, a once-weekly estradiol and levonorgestrel patch
The FDA approved the first generic of Climara Pro, an estradiol and levonorgestrel transdermal system (0.045 mg per day/0.015 mg) applied once a week. The FDA said the generic is therapeutically equivalent to Climara Pro.
-
FDA grants traditional approval for pembrolizumab and Keytruda QLEX for TMB-H solid tumors
On October 16, 2026 the FDA granted traditional approval to pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmh (Keytruda QLEX) for patients with unresectable or metastatic tumor mutational burden-high (TMB-H) solid tumors defined as ≥13 mutations/megabase. In the KEYNOTE-158 study, 220 patients with TMB ≥13 mut/Mb had an objective response rate of 36% (95% CI: 30, 43) and 58% achieved a duration of response of at least 12 months.
-
FDA approves Hibsago for certain adults with chronic hepatitis B
Across pooled Phase 3 trials, 19% of Hibsago recipients met GSK's functional-cure measure 24 weeks after stopping treatment. FDA approval adds Hibsago with existing antiviral therapy for eligible adults without cirrhosis.
-
Five of 10 October FDA approvals were new uses for cancer drugs the FDA had approved before
Five of the 10 FDA approvals dated October 1 to 20, 2026 added a use to a cancer drug the agency had approved before. One, dostarlimab in rectal cancer, is an accelerated approval with a confirmatory trial requirement projected to finish by July 31, 2030.
-
FDA approves once-weekly generic hormone therapy patch for women
The FDA approved the first generic of Climara Pro, a transdermal estradiol and levonorgestrel system (0.045 mg per day/0.015 mg) applied once a week for women with an intact uterus. The generic is therapeutically equivalent to Climara Pro and the most common adverse reactions are application site reaction, vaginal bleeding, breast pain, upper respiratory infection, back pain, depression, pain, headache and flu syndrome (≥5 %).